TAA-Specific Cytotoxic T-Lymphocytes in Treating Participants with Multiple Myeloma

Inclusion Criteria

• PROCUREMENT: Diagnosis of myeloma after receiving at least one treatment regimen
• PROCUREMENT: Patients with life expectancy ≥ 6 weeks
• PROCUREMENT: Hemoglobin (Hgb) > 8.0 (transfusions allowed)
• PROCUREMENT: Patient able to give informed consent
• TREATMENT: Diagnosis of myeloma after receiving at least one treatment regimen; if patient has received an autologous or syngeneic stem cell transplant (SCT) they must be > 90 days post-transplant (Group A) OR following autologous or syngeneic SCT (as adjuvant therapy) and < 90 days post-transplant (Group B)
• TREATMENT: Patients with life expectancy ≥ 6 weeks
• TREATMENT: Pulse oximetry of > 93% on room air in patients who previously received radiation therapy
• TREATMENT: Patients with a Karnofsky score of ≥ 50
• TREATMENT: Patients with bilirubin ≤ 2 x upper limit of normal
• TREATMENT: Aspartate aminotransferase (AST) ≤ 3 x upper limit of normal
• TREATMENT: Hgb > 8.0 (transfusion allowed)
• TREATMENT: Engrafted post-transplant (absolute neutrophil count [ANC] > 500 for at least 3 consecutive days) and ANC > 500 at the time of infusion
• TREATMENT: Patients with a creatinine ≤ 2 x upper limit of normal for age
• TREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this study
• TREATMENT: Patients should have been off conventional therapy for at least 1 week prior to entry in this study (except for lenalidomide, thalidomide, pomalidomide or immune checkpoint inhibitors such as CTLA4 and/or PD-1/PD-L1 inhibitors)
• TREATMENT: Patient able to give informed consent
• TREATMENT: Pregnant women are excluded from this research; the male partner should use a condom; females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligation

Exclusion Criteria

• PROCUREMENT: Patients with severe active infection
• PROCUREMENT: Patients with active human immunodeficiency virus (HIV) infection at time of procurement (can be pending at the time of blood draw)
• TREATMENT: Patients with severe active infection
• TREATMENT: Patients receiving systemic corticosteroid within 48 hours of CTL infusion
• TREATMENT: Pregnant or breast feeding